The New England journal of medicine, 2022-02, Vol.386 (8), p.735-743
- Wang, Eric
- Mi, Xiaoli
- Thompson, Meghan C
- Montoya, Skye
- Notti, Ryan Q
- Afaghani, Jumana
- Durham, Benjamin H
- Penson, Alex
- Witkowski, Matthew T
- Lu, Sydney X
- Bourcier, Jessie
- Hogg, Simon J
- Erickson, Caroline
- Cui, Dan
- Cho, Hana
- Singer, Michael
- Totiger, Tulasigeri M
- Chaudhry, Sana
- Geyer, Mark
- Alencar, Alvaro
- Linley, Adam J
- Palomba, M. Lia
- Coombs, Catherine C
- Park, Jae H
- Zelenetz, Andrew
- Roeker, Lindsey
- Rosendahl, Mary
- Tsai, Donald E
- Ebata, Kevin
- Brandhuber, Barbara
- Hyman, David M
- Aifantis, Iannis
- Mato, Anthony
- Taylor, Justin
- Abdel-Wahab, Omar
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Wang, Eric
- Mi, Xiaoli
- Thompson, Meghan C
- Montoya, Skye
- Notti, Ryan Q
- Afaghani, Jumana
- Durham, Benjamin H
- Penson, Alex
- Witkowski, Matthew T
- Lu, Sydney X
- Bourcier, Jessie
- Hogg, Simon J
- Erickson, Caroline
- Cui, Dan
- Cho, Hana
- Singer, Michael
- Totiger, Tulasigeri M
- Chaudhry, Sana
- Geyer, Mark
- Alencar, Alvaro
- Linley, Adam J
- Palomba, M. Lia
- Coombs, Catherine C
- Park, Jae H
- Zelenetz, Andrew
- Roeker, Lindsey
- Rosendahl, Mary
- Tsai, Donald E
- Ebata, Kevin
- Brandhuber, Barbara
- Hyman, David M
- Aifantis, Iannis
- Mato, Anthony
- Taylor, Justin
- Abdel-Wahab, Omar
- Titel
- Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors
- Ist Teil von
- The New England journal of medicine, 2022-02, Vol.386 (8), p.735-743
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In nine patients with chronic lymphocytic leukemia that responded to the noncovalent BTK inhibitor pirtobrutinib and then developed resistance, analysis revealed a number of new mutations in the BTK kinase domain and occasional mutations in downstream PLCγ2. Despite the inactivity of BTK, alternative pathways of B-cell–receptor signaling were evident.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2114110Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9074143
- Format
- –
- Schlagworte
- Adenine - analogs & derivatives, Adenine - pharmacology, Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors, Agammaglobulinaemia Tyrosine Kinase - genetics, Agammaglobulinaemia Tyrosine Kinase - ultrastructure, Biopsy, Bruton's tyrosine kinase, Cancer, Cell activation, Chronic lymphocytic leukemia, Drug dosages, Drug Resistance, Neoplasm - genetics, Genomic analysis, Hematology, Humans, Kinases, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy, Lymphatic leukemia, Lymphocytes B, Lymphoma, Middle Aged, Mutation, Oncology, Patients, Phospholipase C, Phospholipase C gamma - genetics, Piperidines - pharmacology, Protein Kinase Inhibitors - pharmacology, Protein Kinase Inhibitors - therapeutic use, Proteins, Receptors, Antigen, B-Cell - metabolism, Sequence Analysis, RNA, Signal Transduction - drug effects, Transcription activation, Treatments in Oncology, Tyrosine kinase inhibitors